Compare, Analyse Dishman Pharma with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs TEVA PHARMA (Israel) - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 DISHMAN PHARMA   TEVA PHARMA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
TEVA PHARMA
Dec-13
DISHMAN PHARMA/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs3743,072-   
Low Rs1292,668-   
Sales per share (Unadj.) Rs197.81,762.9-  
Earnings per share (Unadj.) Rs21.2110.1-  
Cash flow per share (Unadj.) Rs34.7252.6-  
Dividends per share (Unadj.) Rs2.0096.40-  
Dividend yield (eoy) %0.83.4 23.7%  
Book value per share (Unadj.) Rs179.91,958.2-  
Shares outstanding (eoy) m80.69848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.31.6 78.1%   
Avg P/E ratio x11.926.1 45.5%  
P/CF ratio (eoy) x7.211.4 63.8%  
Price / Book Value ratio x1.41.5 95.4%  
Dividend payout %9.487.5 10.8%   
Avg Mkt Cap Rs m20,3062,433,768 0.8%   
No. of employees `0000.844.9 1.8%   
Total wages/salary Rs m5,3550-   
Avg. sales/employee Rs Th19,252.733,260.8 57.9%   
Avg. wages/employee Rs Th6,459.50-   
Avg. net profit/employee Rs Th2,064.12,077.8 99.3%   
INCOME DATA
Net Sales Rs m15,9611,494,907 1.1%  
Other income Rs m2650-   
Total revenues Rs m16,2261,494,907 1.1%   
Gross profit Rs m4,103409,381 1.0%  
Depreciation Rs m1,091120,835 0.9%   
Interest Rs m94429,362 3.2%   
Profit before tax Rs m2,334259,184 0.9%   
Minority Interest Rs m01,177 0.0%   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m0-170,140 0.0%   
Tax Rs m624-3,164 -19.7%   
Profit after tax Rs m1,71193,386 1.8%  
Gross profit margin %25.727.4 93.9%  
Effective tax rate %26.7-1.2 -2,188.8%   
Net profit margin %10.76.2 171.6%  
BALANCE SHEET DATA
Current assets Rs m11,0181,009,655 1.1%   
Current liabilities Rs m9,517880,504 1.1%   
Net working cap to sales %9.48.6 108.8%  
Current ratio x1.21.1 101.0%  
Inventory Days Days11091 121.7%  
Debtors Days Days3596 36.3%  
Net fixed assets Rs m16,304488,270 3.3%   
Share capital Rs m1613,680 4.4%   
"Free" reserves Rs m12,9070-   
Net worth Rs m14,5161,660,558 0.9%   
Long term debt Rs m4,189764,379 0.5%   
Total assets Rs m29,8053,416,342 0.9%  
Interest coverage x3.59.8 35.3%   
Debt to equity ratio x0.30.5 62.7%  
Sales to assets ratio x0.50.4 122.4%   
Return on assets %8.93.6 248.0%  
Return on equity %11.85.6 209.6%  
Return on capital %17.54.9 355.5%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Net fx Rs m4,2550-   
CASH FLOW
From Operations Rs m2,786238,211 1.2%  
From Investments Rs m-1,529-84,408 1.8%  
From Financial Activity Rs m-941-285,750 0.3%  
Net Cashflow Rs m316-131,947 -0.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 73.59 Rs / USD

Compare DISHMAN PHARMA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  

Compare DISHMAN PHARMA With: ELDER PHARMA  ALEMBIC PHARMA  UNICHEM LAB  CIPLA  SANOFI INDIA  



Today's Market

Sensex Falls 471 Points, Nifty Ends Below 14,700; Tata Steel & JSW Steel Top Losers(Closing)

Indian share markets witnessed selling pressure throughout the day today and ended lower.

Related Views On News

What's Behind the Rally in Pharma Stocks? (Views On News)

May 11, 2021

The second wave of Covid has given a new lease of life to pharma stocks.

Why Did Alembic Pharma Shares Fall Today? (Views On News)

May 5, 2021

Covid-led supply disruptions of API fuel Alembic Pharma's global prospects.

More Views on News

Most Popular

The Next Smallcap Winners (Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Time to Buy Smallcaps? (Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

Are the Stock Markets Deaf to Covid Agony? (Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

My Secret to Find Breakthrough Stocks (Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

More
-->

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

FREE Event: Discover Your First Stock for a Potential Rs 7 Crore in Long-term Wealth
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
Free Report: The Secret to Increasing Your Trading Profits Daily!
No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

FEATURED VIDEOS

Top Pick for Next Decade

The 'Big' Money is in this 'Small' Detail

Stability, Quality or Green Stocks for 2021?

Market Crash: Picture Abhi Baaki Hai?

More Featured Videos

MARKET STATS